(CCRN) Cross Country Healthcare - Ratings and Ratios

Cross Country Healthcare, Inc. (NASDAQ:CCRN) is a leading provider of healthcare workforce management solutions in the United States. The company operates through two primary segments: Nurse and Allied Staffing, and Physician Staffing. Its Nurse and Allied Staffing segment offers comprehensive talent acquisition and workforce management services, including temporary and permanent placements of nurses, allied professionals, and healthcare leaders. The segment also provides education and in-home care services, as well as outsourcing solutions such as MSP, VMS, and RPO. This division serves a diverse range of healthcare facilities, including hospitals, clinics, schools, and government institutions, under the Cross Country brand.

The Physician Staffing segment, operating under the Cross Country Locums brand, specializes in placing physicians, nurse practitioners, and physician assistants in temporary roles across various healthcare settings. This segment caters to acute and non-acute care facilities, medical groups, and managed care organizations. Cross Country Healthcare has established itself as a trusted partner in addressing staffing challenges in the healthcare industry, leveraging its extensive network and consultative approach to deliver tailored solutions.

From a technical perspective, CCRN is currently trading at $17.27, slightly below its 20-day SMA of $17.98 and 50-day SMA of $18.06. The stocks 200-day SMA of $14.93 indicates a recent upward trend. Average daily volume stands at 443,492 shares, with an ATR of 0.11, suggesting moderate volatility. On the fundamental side, the company has a market cap of $584.22 million, with a forward P/E ratio of 32.89, reflecting investor expectations of future earnings growth. The P/B ratio of 1.38 indicates the stock is trading at a modest premium to its book value, while the negative RoE of -0.42 raises concerns about profitability.

3-Month Forecast: Based on and , CCRN is expected to face resistance near $18, driven by its 20-day and 50-day SMAs. The stock may experience short-term upward momentum due to its recent upward trend, but the high forward P/E and negative RoE could limit long-term gains. The low ATR suggests volatility may remain subdued, with potential sideways trading in the first two months. By the third month, the stock may pull back toward its 200-day SMA of $14.93 if earnings fail to meet expectations.